City of Hope researchers identify biomarkers that may detect risk of advanced prostate cancer in Black men

From the desk of Kimryn Rathmell: What to read before these beautiful days slip away
My summer reading challenged me to see people, purpose, and complexity in a new way

One of the great pleasures of summer is having more time to read.

August 14, 2026

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

August 14, 2026

Vol.52 No.32

Clinical Roundup

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

As focal therapy gains popularity as a less invasive treatment option for some men with prostate cancer, a national study led by researchers at the University of Pittsburgh found that some men may be receiving treatment that is either unnecessary or not aggressive enough for their cancer.

August 14, 2026

Vol.52 No.32

Podcast The Directors

The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access

New pressures notwithstanding, being a cancer center director is still a dream job, two of the nation’s newest cancer center directors said.

August 07, 2026

Vol.52 No.31

By Claire Marie Porter and Paul Goldberg

Drugs & Targets

FDA approves Pluvicto for mHSPC

FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer.

August 07, 2026

Vol.52 No.31

Regulatory News

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

In a video captioned “The High-T Department of War” and posted on X, Secretary of Defense Pete Hegseth announced that he was authorizing a screening program for troops to ensure “you have the right testosterone levels to operate at your absolute best.”

July 24, 2026

Vol.52 No.29

By Claire Marie Porter

City of Hope researchers identify biomarkers that may detect risk of advanced prostate cancer in Black men

YOU MAY BE INTERESTED IN

From the desk of Kimryn Rathmell: What to read before these beautiful days slip away
My summer reading challenged me to see people, purpose, and complexity in a new way

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access

FDA approves Pluvicto for mHSPC

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

Renew today!

Subscriber content

Never miss an issue!

Login

City of Hope researchers identify biomarkers that may detect risk of advanced prostate cancer in Black men

YOU MAY BE INTERESTED IN

From the desk of Kimryn Rathmell: What to read before these beautiful days slip awayMy summer reading challenged me to see people, purpose, and complexity in a new way

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access

FDA approves Pluvicto for mHSPC

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warningsExperts caution the move amounts to a “huge, unregulated, natural experiment”

Never miss an issue!

Login

From the desk of Kimryn Rathmell: What to read before these beautiful days slip away
My summer reading challenged me to see people, purpose, and complexity in a new way

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”